Cargando…

The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies

It is often argued that DNA nanotechnology has a multitude of possible applications. However, despite great advances in the understanding of the fundamental principles of the field, to date, there has been comparatively little commercial activity. Analysis of patent applications and company case stu...

Descripción completa

Detalles Bibliográficos
Autor principal: Dunn, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024392/
https://www.ncbi.nlm.nih.gov/pubmed/31963295
http://dx.doi.org/10.3390/molecules25020377
_version_ 1783498424908251136
author Dunn, Katherine E.
author_facet Dunn, Katherine E.
author_sort Dunn, Katherine E.
collection PubMed
description It is often argued that DNA nanotechnology has a multitude of possible applications. However, despite great advances in the understanding of the fundamental principles of the field, to date, there has been comparatively little commercial activity. Analysis of patent applications and company case studies suggests that this is now starting to change. The number of patent application filings is increasing, and new companies are being formed to exploit technologies based on nanoscale structures and devices made from DNA. There are parallels between the commercial developments in this field and those observed in other areas of innovation. Further commercialization is expected and new players will emerge.
format Online
Article
Text
id pubmed-7024392
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70243922020-03-11 The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies Dunn, Katherine E. Molecules Review It is often argued that DNA nanotechnology has a multitude of possible applications. However, despite great advances in the understanding of the fundamental principles of the field, to date, there has been comparatively little commercial activity. Analysis of patent applications and company case studies suggests that this is now starting to change. The number of patent application filings is increasing, and new companies are being formed to exploit technologies based on nanoscale structures and devices made from DNA. There are parallels between the commercial developments in this field and those observed in other areas of innovation. Further commercialization is expected and new players will emerge. MDPI 2020-01-16 /pmc/articles/PMC7024392/ /pubmed/31963295 http://dx.doi.org/10.3390/molecules25020377 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dunn, Katherine E.
The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title_full The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title_fullStr The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title_full_unstemmed The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title_short The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies
title_sort business of dna nanotechnology: commercialization of origami and other technologies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024392/
https://www.ncbi.nlm.nih.gov/pubmed/31963295
http://dx.doi.org/10.3390/molecules25020377
work_keys_str_mv AT dunnkatherinee thebusinessofdnananotechnologycommercializationoforigamiandothertechnologies
AT dunnkatherinee businessofdnananotechnologycommercializationoforigamiandothertechnologies